Circularity’s D’OXYVA® completely noninvasive transdermal drug delivery (NTD) is a powerful, noninvasive biotech solution, which is the only real regenerative drug+device combo clinically studied in randomized, double-blind, placebo-controlled trials on people and identified as a Non-Significant Risk (NSR) device. It has shown significant lasting improvements in oxygenated blood flow, especially in the microcirculation as recorded with a variety of FDA-cleared diagnostics.
Circularity Healthcare (“Circularity”) operates a state-of-the-art supply chain and Quality Management System (QMS) for manufacturing. Circularity received a certificate of registration in 2015 to IS EN ISO13485:2012 (European Union) and ISO13485:2003 under CMDCAS (Canada) it had started implementing in 2013.
D’OXYVA® (deoxyhemoglobin vasodilator) is a CE-marked medical device (Class I, low risk) in certain markets for delivery of liquid medications via the skin. Circularity is seeking approvals via the U.S. FDA and in other countries for delivery of medical gases such as medical/pharmaceutical carbon dioxide (USP) via a novel patented and patent-pending non-invasive skin delivery route with D’OXYVA® as solution for various widespread medical conditions.
Circularity Healthcare’s platform biotech solution, D’OXYVA® is utilizing cGMP-compliant pharmaceutical-grade carbon dioxide registered with FDA for use in the inhalation route like anesthesia as a non-toxic and simple molecule. D’OXYVA® enjoys an investigational device exemption (IDE) status due to having been categorized in successful IRB-approved human studies as a non-significant risk (NSR) medical device.
Ask your physician before using D’OXYVA® FOR MEDICAL PURPOSES, prescription only. The D’OXYVA® noninvasive transdermal drug delivery delivery device holds a growing number of Class I (low risk or non-significant risk medical device) licenses around the world. Purchase for non-medical purposes is available on doxyva.com and in various Circularity-authorized retail stores online and offline. Circularity’s novel D’OXYVA® patented transdermal drug delivery pathway with medical/pharmaceutical carbon dioxide (USP) has not been evaluated yet by the U.S. Food and Drug Administration (FDA) and is not intended to diagnose, treat, cure, or prevent any disease. The information provided herein is for educational and research purposes and is not intended to replace medical advice. Individual results may vary.